Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
source : Www.vynetherapeutics.com save search
SEC Filing: Form 4
Published: 2023-01-04 (Crawled : 00:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 2.22%
H: 159.79%
C: 69.32%
VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis
Published: 2023-04-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 7.03%
H: 50.75%
C: 33.13%
vyn201 positive fibrosis preclinical therapeutics
VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions
Published: 2023-05-01 (Crawled : 12:20) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
vyn202 candidate treatment therapeutics potential
SEC Filing: Form 8-K
Published: 2023-05-01 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 18.63%
C: 14.83%
VYNE Investor Relations Presentation
Published: 2022-11-10 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 16.0%
C: 7.96%
presentation
VYNE Investor Relations Presentation
Published: 2023-03-30 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 2.5%
H: 13.53%
C: 13.53%
presentation
VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event
Published: 2022-01-03 (Crawled : 13:30) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 12.75%
C: 10.78%
therapeutics
SEC Filing: Form 8-K
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 10-Q
Published: 2023-05-11 (Crawled : 21:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 12.54%
C: 2.01%
SEC Filing: Form 8-K
Published: 2023-01-12 (Crawled : 23:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 2.52%
H: 11.54%
C: 8.92%
VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201
Published: 2023-02-15 (Crawled : 14:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 2.0%
H: 11.48%
C: -1.68%
vyn201 trial therapeutics positive
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
Published: 2022-05-18 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: -5.77%
H: 11.26%
C: 4.66%
conference therapeutics
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
Published: 2022-03-30 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: -0.81%
H: 10.86%
C: 7.89%
vyn201 preclinical positive injection pre-clinical
SEC Filing: Form 8-K
Published: 2022-03-30 (Crawled : 01:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: -0.81%
H: 10.86%
C: 7.89%
VYNE Investor Relations Presentation
Published: 2023-04-20 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: -7.17%
H: 9.9%
C: 5.8%
presentation
VYNE Investor Relations Presentation
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
presentation
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-04-07 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
fmx114 treatment dermatitis trial therapeutics positive phase 2b
SEC Filing: Form 8-K
Published: 2022-04-07 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 13.11%
H: 9.62%
C: -3.19%
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
Published: 2022-03-17 (Crawled : 12:30) - vynetherapeutics.com
DERM | $3.42 -3.39% 36K
|
|
| O: 1.76%
H: 4.32%
C: -2.81%
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 8.8%
C: 6.09%
financial results therapeutics report results
SEC Filing: Form 8-K
Published: 2022-03-17 (Crawled : 18:00) - vynetherapeutics.com
VYNE | $2.39 3.02% 40K
|
Health Technology
|
| O: 0.0%
H: 8.8%
C: 6.09%
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.